TrialEuropean journal of clinical pharmacology2017

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.

Angela W Dymond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.